CA3120349A1 - Suicide gene - Google Patents

Suicide gene Download PDF

Info

Publication number
CA3120349A1
CA3120349A1 CA3120349A CA3120349A CA3120349A1 CA 3120349 A1 CA3120349 A1 CA 3120349A1 CA 3120349 A CA3120349 A CA 3120349A CA 3120349 A CA3120349 A CA 3120349A CA 3120349 A1 CA3120349 A1 CA 3120349A1
Authority
CA
Canada
Prior art keywords
tnf
alpha
cell
vector
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3120349A
Other languages
English (en)
French (fr)
Inventor
Katy REZVANI
Elizabeth SHPALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68848450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3120349(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3120349A1 publication Critical patent/CA3120349A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/25—Suicide switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA3120349A 2018-11-19 2019-11-18 Suicide gene Pending CA3120349A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862769405P 2018-11-19 2018-11-19
US62/769,405 2018-11-19
US201862773372P 2018-11-30 2018-11-30
US62/773,372 2018-11-30
US201962791464P 2019-01-11 2019-01-11
US62/791,464 2019-01-11
PCT/US2019/062009 WO2020106619A1 (en) 2018-11-19 2019-11-18 Suicide gene

Publications (1)

Publication Number Publication Date
CA3120349A1 true CA3120349A1 (en) 2020-05-28

Family

ID=68848450

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3120349A Pending CA3120349A1 (en) 2018-11-19 2019-11-18 Suicide gene

Country Status (18)

Country Link
US (1) US20220023343A1 (enExample)
EP (1) EP3883959A1 (enExample)
JP (1) JP2022513099A (enExample)
KR (1) KR20210093977A (enExample)
CN (1) CN113272320A (enExample)
AU (1) AU2019384115A1 (enExample)
BR (1) BR112021009634A2 (enExample)
CA (1) CA3120349A1 (enExample)
CL (1) CL2021001300A1 (enExample)
CO (1) CO2021007824A2 (enExample)
EC (1) ECSP21044662A (enExample)
IL (1) IL283242A (enExample)
MX (1) MX2021005847A (enExample)
PE (1) PE20211236A1 (enExample)
PH (1) PH12021551142A1 (enExample)
SG (1) SG11202105238YA (enExample)
TW (1) TW202039538A (enExample)
WO (1) WO2020106619A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311837A (en) 2021-10-20 2024-05-01 Takeda Pharmaceuticals Co Compositions targeting bcma and methods of use thereof
EP4493581A1 (en) * 2022-03-18 2025-01-22 University of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817955A1 (de) 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
US6143866A (en) 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1994000555A2 (en) * 1992-06-25 1994-01-06 Cetus Oncology Corporation Compositions for the inhibition of protein hormone formation and uses thereof
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
EA035898B1 (ru) * 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
AU2016306209B2 (en) * 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
CN107245106B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd10的嵌合抗原受体及其应用
CN107337737B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种嵌合抗原受体及其应用
CN107245107B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd20的嵌合抗原受体及其应用
CN107312098B (zh) * 2017-07-18 2020-06-12 深圳市免疫基因治疗研究院 一种基于cd22的嵌合抗原受体及其应用
CN107312097B (zh) * 2017-07-18 2020-06-16 深圳市免疫基因治疗研究院 一种基于cd30的嵌合抗原受体及其应用
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
KR20210093977A (ko) 2021-07-28
CL2021001300A1 (es) 2022-03-18
MX2021005847A (es) 2021-09-23
IL283242A (en) 2021-07-29
SG11202105238YA (en) 2021-06-29
EP3883959A1 (en) 2021-09-29
PE20211236A1 (es) 2021-07-09
TW202039538A (zh) 2020-11-01
CO2021007824A2 (es) 2021-06-30
WO2020106619A1 (en) 2020-05-28
US20220023343A1 (en) 2022-01-27
PH12021551142A1 (en) 2021-10-25
CN113272320A (zh) 2021-08-17
JP2022513099A (ja) 2022-02-07
ECSP21044662A (es) 2021-09-30
BR112021009634A2 (pt) 2021-08-10
AU2019384115A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
US11000549B2 (en) Methods of using chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
AU2022200381A1 (en) Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof
US20200115461A1 (en) Compositions and methods for adoptive cell therapies
JP7382829B2 (ja) キメラ抗原受容体を発現するｔ細胞
RS62870B1 (sr) Himerni antigenski receptori sa ciljanim delovanjem na receptore spregnute sa g-proteinom i njihove upotrebe
JP2022528030A (ja) 多機能性融合タンパク質及びその使用
CN111819186A (zh) 表达嵌合抗原受体的免疫细胞
JP2022546315A (ja) キメラ抑制性受容体
CA3019509A1 (en) Inhibition of tgfbeta in immunotherapy
KR102822623B1 (ko) T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
TW202342734A (zh) 具有抗-cd19/抗-cd22嵌合抗原受體之基因工程細胞及其用途
CN114828862A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
TW202144396A (zh) 抑制性嵌合受體架構
KR20240004680A (ko) 키메라 수용체 및 이의 사용 방법
CN112166186A (zh) 用于t细胞恶性肿瘤的免疫治疗的嵌合抗原受体和cd2的基因编辑
US20220023343A1 (en) Suicide gene
JP2025519448A (ja) 膜結合ｉｌ１２を用いて遺伝子操作した人工多能性幹細胞に由来する免疫エフェクター細胞ならびにその使用
JP2025522360A (ja) Ｃｄ１６変異体およびｎｋｇ２ｄを発現する遺伝子操作した細胞ならびにその使用
JP2024514522A (ja) 遺伝子導入ベクターおよび細胞を操作する方法
EA045791B1 (ru) Суицидный ген
WO2024254515A2 (en) Systems and methods to direct cellular therapies in vivo to an organ
Kamat et al. CAR-T Cells: Design Principles, Core Concepts, and Clinical Applications
CN117529498A (zh) 嵌合受体及其使用方法
HK40001773A (en) Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103